+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vaccines Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5351788
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbott
  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline
  • NOVARTIS AG
  • Pfizer
Vaccines Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global vaccines market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Vaccines Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:

1) By Type: Anti-Infective Vaccines; Autoimmunity; Others (Cancer and Others)
2) By Technology: Conjugate Vaccines; Inactivated and Subunit Vaccines; Live Attenuated Vaccines; Recombinant Vaccines; Toxoid Vaccines
3) By Route of Administration: Intramuscular (IM); Subcutaneous (SC); Oral; Others
4) By Valance: Monovalent; Multivalent
5) By Distribution Channel: Institutional Sale; Hospital Pharmacies; Retail Pharmacies

Companies Mentioned: AstraZeneca; Emergent Biosolutions; Glaxosmithkline; Merck; Pfizer

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline
  • NOVARTIS AG
  • Pfizer
1. Executive Summary

2. Vaccines Market Characteristics

3. Vaccines Market Trends And Strategies

4. Impact Of COVID-19 On Vaccines

5. Vaccines Market Size And Growth
5.1. Global Vaccines Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Vaccines Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Vaccines Market Segmentation
6.1. Global Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Anti-Infective Vaccines
  • Autoimmunity
  • Others (Cancer And Others)
6.2. Global Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
6.3. Global Vaccines Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Oral
  • Others
6.4. Global Vaccines Market, Segmentation By Valance, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Monovalent
  • Multivalent
6.5. Global Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Institutional Sale
  • Hospital Pharmacies
  • Retail Pharmacies
7. Vaccines Market Regional And Country Analysis
7.1. Global Vaccines Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Vaccines Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Vaccines Market
8.1. Asia-Pacific Vaccines Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Vaccines Market
9.1. China Vaccines Market Overview
9.2. China Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Vaccines Market
10.1. India Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Vaccines Market
11.1. Japan Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Vaccines Market
12.1. Australia Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Vaccines Market
13.1. Indonesia Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Vaccines Market
14.1. South Korea Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Vaccines Market
15.1. Western Europe Vaccines Market Overview
15.2. Western Europe Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Vaccines Market
16.1. UK Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Vaccines Market
17.1. Germany Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Vaccines Market
18.1. France Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.2. France Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Vaccines Market
19.1. Eastern Europe Vaccines Market Overview
19.2. Eastern Europe Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Vaccines Market
20.1. Russia Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Vaccines Market
21.1. North America Vaccines Market Overview
21.2. North America Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Vaccines Market
22.1. USA Vaccines Market Overview
22.2. USA Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Vaccines Market
23.1. South America Vaccines Market Overview
23.2. South America Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Vaccines Market
24.1. Brazil Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Vaccines Market
25.1. Middle East Vaccines Market Overview
25.2. Middle East Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Vaccines Market
26.1. Africa Vaccines Market Overview
26.2. Africa Vaccines Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Vaccines Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Vaccines Market Competitive Landscape And Company Profiles
27.1. Vaccines Market Competitive Landscape
27.2. Vaccines Market Company Profiles
27.2.1. AstraZeneca
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Emergent Biosolutions
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Glaxosmithkline
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Merck
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Pfizer
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Vaccines Pipeline Analysis

29. Key Mergers And Acquisitions In The Vaccines Market

30. Vaccines Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline
  • NOVARTIS AG
  • Pfizer
Major players in the vaccines market are AstraZeneca, Emergent Biosolutions, GlaxoSmithKline, Merck, and Pfizer Inc.

The global vaccines market is expected to decline from $56.02 billion in 2020 to $55.97 billion in 2021 at a compound annual growth rate (CAGR) of -0.1%. The slow decline is mainly due to the outbreak of COVID-19 that has led to deferment of immunocompromised treatments. The market is expected to reach $85.93 billion in 2025 at a CAGR of 11.3%.

The vaccines market consists of sales of vaccines and related services. This industry includes establishments that produce anti-infective vaccines, autoimmunity vaccines and vaccines for cancer and other diseases. Vaccines create antibody-antigen reaction that helps in attaining resistance to the disease causing organism. Vaccines include recombinant vaccines, conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines and others.

The market covered in this report is segmented by type into anti-infective vaccines, autoimmunity, others (cancer and others); by technology into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines; by route of administration into intramuscular (IM), subcutaneous (SC), oral, others; by valance into monovalent, multivalent; by distribution channel into institutional sale, hospital pharmacies, retail pharmacies.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The vaccines market growth is limited due to severe shortage of skilled healthcare professionals for developing biologics drugs which requires specialized skillsets. These skillsets are limited to some research organizations and medical equipment companies in the USA and Europe, this is expected to be a major restraint on the market. As of 2018, 40% of the biopharma industry was facing difficulties in hiring for process development staff due to shortage of talent. This shortage also led to rise in competition and salaries for the limited talent pool available for biologics talent, thereby further limiting growth of the market.

The vaccines market has been witnessing multiple strategic initiatives and mergers and acquisitions in the recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. For instance, in February 2019, Bharat Biotech acquired Chiron Behring Vaccines, a clinical biotechnology company, one of the leading manufacturers of rabies vaccines across the globe. Similarly, in October 2018, Emergent BioSolutions, a multinational specialty biopharmaceutical company, acquired PaxVax for $270 million, and Sanofi acquired Protein Sciences for $650 million. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favourable interest rates globally.

In October 2018, Emergent BioSolutions, a multinational specialty biopharmaceutical company, acquired PaxVax for $270 million. This acquisition would strengthen and expand Emergent BioSolution's product portfolio with PaxVax's typhoid vaccine Vivotif, cholera vaccine Vaxchora and additional clinical-stage vaccine used in the prevention of typhoid fever, cholera, chikungunya and other emerging infectious diseases. PaxVax is a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. PaxVax was founded in 2006 and is headquartered in Cayman Islands, a British Overseas Territory.

Rising awareness on immunization and vaccination benefits in emerging markets is consistently driving the global vaccines market growth. World Health Organization (WHO) is taking initiatives to increase awareness of immunization through global vaccine action plan (GVAP) and global Immunization vision and strategy (GIVS). They aim to strengthen routine immunization, control morbidity and mortality from vaccine preventable diseases and help countries to immunize more people with a greater range of vaccines. The Organization accomplishes this work through its biological programme, the WHO Collaborating Centers, and the WHO Expert Committee on Biological Standardization (ECBS). In 2019, according to the WHO, approximately 85% of infants globally (116 million infants) received 3 doses of diphtheria-tetanus-pertussis (DTP3) vaccine, protecting them against infectious diseases that can cause serious illness and disability or be fatal. Furthermore, 125 countries reached at least 90% coverage of the DTP3 vaccine in 2019.

The Food and Drug Administration (FDA) is the National Regulatory Authority (NRA) in the United States responsible for assuring quality, safety, and effectiveness of all vaccines for human use. Center for Biologics Evaluation and Research (CBER) within the US FDA is responsible for regulating vaccines market. Governments across the world are encouraging the research and development of biologics in order to develop more targeted therapies and vaccines for various diseases. In May 2014, the US’s FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. In 2016, FDA also removed a rule (Section 610.21 of the FDA code) which specified minimal potency limits for certain antibodies and antigens.. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown
  • AstraZeneca
  • Emergent Biosolutions
  • Glaxosmithkline
  • Merck
  • Pfizer
  • Sanofi Pasteur
  • Abbott
  • Astellas Pharma
  • Bavarian Nordic
  • CSL Limited
  • Daiichi Sankyo Company
  • Johnson & Johnson
  • Mitsubishi Tanabe Pharma Corporation
  • Serum Institute of India
  • Takeda Pharmaceutical Co. Ltd.
  • Biological E Limited
  • BiondVax Pharmaceuticals Ltd
  • Bristol-Myers Squibb
  • Inovio Pharmaceuticals Inc.
  • Madison Vaccines Incorporated
  • NOVARTIS AG
  • Novavax Inc.
  • Panacea Biotec
  • Sinovac Biotech Ltd.
  • Valneva SE
  • VBI Vaccine Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll